Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) are at risk of atrial fibrillation or flutter (AFF) due to cardiac remodeling and kidney complications. Finerenone, a novel, selective, nonsteroidal mineralocorticoid receptor antagonist, inhibited cardiac remodeling in preclinical models.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): J Am Coll Cardiol

Title: Journal of the American College of Cardiology

Publisher: Elsevier BV

ISSN (Electronic): 1558-3597

ISSN (Print): 0735-1097

Publication date (Electronic): July 13 2021

Volume: 78

Issue: 2

Affiliations

[1 ] National and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece. Electronic address: geros@otenet.gr.

[2 ] Department of Medicine, University of Chicago Medicine, Chicago, Illinois, USA.

[3 ] Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA.

[4 ] Richard L. Roudebush VA Medical Center and Indiana University, Indianapolis, Indiana, USA.

[5 ] Steno Diabetes Center Copenhagen, Gentofte, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

[6 ] Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain; Faculty of Sport Sciences, European University of Madrid, Madrid, Spain.

[7 ] Department of Medicine, University of Mississippi, Jackson, Mississippi, USA.

[8 ] National Heart Centre Singapore and Duke-National University of Singapore, Singapore.

[9 ] Research and Development, Preclinical Research Cardiovascular, Bayer AG, Wuppertal, Germany.

[10 ] Study Medical Experts, Bayer PLC, Reading, United Kingdom.

[11 ] Research and Development, Statistics and Data Insights, Bayer AG, Wuppertal, Germany.

[12 ] Cardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany.

[13 ] Department of Cardiology (CVK), and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany.

Article

Publisher Item ID: S0735-1097(21)04966-4

DOI: 10.1016/j.jacc.2021.04.079

PubMed ID: 34015478

SO-VID: 0ff6fed5-9a8c-4f0a-80c9-9311fd83fb9d

History

Keywords: new-onset atrial fibrillation,mineralocorticoid receptor antagonist,finerenone,clinical trial,chronic kidney disease,type 2 diabetes

Data availability:

Keywords: new-onset atrial fibrillation, mineralocorticoid receptor antagonist, finerenone, clinical trial, chronic kidney disease, type 2 diabetes

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.

Read this article at

Abstract

Related collections

Drug Repurposing

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 57

Cited by 45